Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2019 | Tisagenlecleucel in R/R follicular lymphoma: ELARA data

Michael Dickinson • 20 Jun 2019
ICML 2019
B-Cell Lymphoma Follicular Lymphoma Lymphoma Non-Hodgkin Lymphoma Tisagenlecleucel
ELARA

Michael Dickinson, MBBS, DMedSc, FRACP, FRACPA, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the ELARA trial (NCT03568461). This Phase II trial assessed the efficacy and safety of tisagenlecleucel in adult patients with relapsed/refractory follicular lymphoma. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Michael Dickinson

4:18
Pembrolizumab monotherapy for older/ABVD-ineligible patients with Hodgkin lymphoma
Michael Dickinson • 16 Jun 2023
3:48
COALITION: glofitamab + R-CHOP or glofitamab + pola-R-CHP in high-risk DLBCL
Michael Dickinson • 16 Jun 2023
10:25
Key highlights in NHL: updates in MCL, the role of transplantation, and novel bispecific antibodies
Michael Dickinson et al. • 12 Dec 2022
3:49
The challenges in developing bispecific antibodies for non-Hodgkin lymphoma
Michael Dickinson • 30 Sep 2022

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals